In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life ...

Patients with pulmonary fibrosis (PF) and pulmonary hypertension (PH) have superior transplant-free survival outcomes if they receive pulmonary vasodilator therapy in combination with antifibrotic ...

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterised by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs ...

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team of Columbia and UCSD researchers may have found a clever solution that ...

The patients' lungs got better. The importance of this finding is that pulmonary fibrosis after COVID-19 tends to resolve, while in idiopathic pulmonary fibrosis (IPF) it always progresses.

Drug-induced lung disease cases in France mostly involved ILD, pulmonary edema, and pulmonary fibrosis, largely linked to cancer and CV drugs.